Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued to clients and investors on Sunday. The firm set a “sell” rating on the stock.

MBRX has been the subject of several other reports. Roth Mkm reaffirmed a “buy” rating and issued a $40.00 target price on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group dropped their target price on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th.

Moleculin Biotech Price Performance

MBRX stock opened at $3.52 on Friday. The firm’s fifty day moving average is $4.52 and its 200 day moving average is $6.91. Moleculin Biotech has a 52 week low of $3.35 and a 52 week high of $15.75.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings results on Friday, May 10th. The company reported ($2.02) earnings per share for the quarter, beating the consensus estimate of ($3.59) by $1.57. On average, research analysts forecast that Moleculin Biotech will post -8.79 earnings per share for the current fiscal year.

Institutional Trading of Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Atticus Wealth Management LLC bought a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned approximately 0.17% of Moleculin Biotech as of its most recent filing with the Securities & Exchange Commission. 15.52% of the stock is currently owned by institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.